PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29466360-5	2018	OBJECTIVES: We set out to assess whether combining metformin and esomeprazole would additively reduce sFlt-1 and soluble endoglin secretion and reduce endothelial dysfunction (verses drug alone).	Esomeprazole	65-77	endoglin	Homo sapiens	121-129	
26510725-5	2015	Esomeprazole potently decreases soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin secretion from placenta and endothelial cells, and has biological actions to mitigate endothelial dysfunction and oxidative stress.	Esomeprazole	0-12	endoglin	Homo sapiens	88-96	
26510725-12	2015	We will examine whether esomeprazole can decrease serum sFlt-1 and soluble endoglin levels and we will record the safety of esomeprazole in these pregnancies.	Esomeprazole	24-36	endoglin	Homo sapiens	75-83